• Customer
  • Integrated
Company
introduction
Dongsung pharmaceutical with 60 years of history provides customer oriented total services and future oriented marketing which covers cosmetics and finished medicine.
홈으로 바로가기
상품 큰이미지05
제품의 제품명, 제품구분, 분류군, 보험코드, 효능효과표
Product name : Carodiet Tab. 5mg/20mg
Product division : ETC drug
Classification group : Circulatory medication
Insurance code : 643201480
Efficacy and effect : This drug is used for pat..
 
Basic information
    • 성상 아이콘 이미지
    • Appearance
    • White oval film-coated tablet
    • 용법용량 아이콘 이미지
    • DOSAGE AND ADMINISTRATION
    • This drug is administered only to adults, and the dose should be individualized in each patient based on the efficacy and tolerability of each amlodipine / atorvastatin.
      Amlodipine (S-amlodipine)
       Adults: Amlodipine (S-amlodipine) is administered orally 5 (2.5) mg once per day and can be increased up to 10 (5) mg / day depending on the patient's response. Dose should be appropriately adjusted according to symptoms.
      Atorvastatin
       Patients before and after the administration of atorvastatin should be given a standard cholesterol-lowering diet, and may take it at any time during the day, regardless of meal.
       1. Patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson Type IIa and IIb)
       The recommended initial dose for this drug is 10 mg once a day, but 20 mg or 40 mg once a day for patients requiring a reduction in LDL-cholesterol (requiring a reduction in LDL-cholesterol level of more than 45% Only). This drug is administered once a day in a dose range of 10 mg to 80 mg, and may be administered at any time during the day regardless of food.
       The initial dose and maintenance dose should be individualized according to the characteristics of the patient, taking into account the therapeutic goals and response, and the lipid levels should be analyzed within 2 to 4 weeks after initiation and / Should be adjusted.
       2. Patients with homozygous familial hypercholesterolemia
       The dosage of this drug is 10 mg to 80 mg once a day. It should be administered in combination with other lipid-lowering therapies (eg, LDL collection), or if such lipid-lowering therapy is not feasible.
       3. Patients with kidney failure
       Renal disease does not affect the plasma concentration of atorvastatin or the LDL-cholesterol lowering effect, so there is no need to adjust the dose.
       4. Elderly people
       The efficacy and safety of elderly people over 70 years of age are similar to those of adult patients.
    • 성분및함량 아이콘 이미지
    • Ingredient / content
    • per 1 tablet
      Carodiet tab 5mg / 10mg
        - amlodipine besylate 6.94 mg
        - Atorvastatin calcium 10.36 mg
      Carodiet tab 5mg / 20mg
        - amlodipine besylate 6.94 mg
        - Atorvastatin calcium 20.72 mg
    • 규격 아이콘 이미지
    • standard
    • 30, 100 tablet
    • 저장방법 아이콘 이미지
    • How to Save
    • Airtight container, Stored at room temperature(15~30℃)
    • 사용기간 아이콘 이미지
    • Period of use
    • 24 months from manufacture date
    • 효능효과 아이콘 이미지
    • Efficacy and effect
    • This drug is used for patient who has to use two drugs(Amlodipine(S-Amlodipine) and Atorvastatin) simultaneously.

      Amlodipine(S-amlodipine)
      1. Cardiac ischemia due to hypertension, fixed obstruction of coronary artery(stable angina), or vasospasm and vasoconstriction (variant angina) in coronary arterial system
      2. In patient confirmed of coronary disease with recent angiography with no cardiac failure or more than 40% of EF
      - Reduces risk of hospitalization due to angina
      - Reduces risk of coronary arterioplasty

      Atrovastatin
      1. Reduction of risk for following cardiovascular diseases
      1) Though there are no clinical evidence of coronary disease, in adult patient with multiple risk factors for coronary disease (age, smoking, hypertension, low HDL-cholesterol, or familial history of early coronary disease
      가. Reduces risk of myocardial infarction
      나. Reduces risk of stroke
      다. Reduces risk of angioplasty and chronic stable angina
      2) Though there is no clinical evidence for oronary disease, in type 2 DM patients with multiple risk factors for coronary disease (retinopathy, albuminuria, smoking, or hypertension, etc.)
      (1) reduces risk for myocardiac infarction
      (2) Reduces risk for stroke
      3) In adult patient with clinical evidence of coronary disease
      (1) Reduces risk for non-lethal myocardial infarction
      (2) Reduces risk for lethal and non-lethal stroke
      (3) Reduces risk for angioplasty
      (4) Reduces risk for admission due to congestive heart failure
      (5) Reduces risk for angina
      2.Dietary supplement that reduces elevated total cholesterol, LDL-cholesterol, Apo-B protein, and triglyceride in patients with primary hypercholesterolemia(heterozygous familial and non-familial) and mixed dyslipidemia (Fredrickson Type Ⅱa and Ⅱb) and increases HDL-cholesterol
      3. Dietary supplement for patients with high serum triglyceride(Fredrickson Type IV)
      4. Primary dysbetalipoproteinemia (Fredrickson Type III) that does not show adequate response to dietary treatment
      5. When other lipid lowering agent (e.g. LDL-apheresis) is simultaneously used or treatment with other lipid lowering agents cannot reduce total cholesterol and LDL-cholesterol in homozygous familial hypercholesterolemia